Full-Time
Industrial Business Management Trainee
Updated on 9/9/2026
Pfizer
10,001+ employees
Biopharmaceutical company develops medicines and vaccines
No salary listed
Freiburg im Breisgau, Germany
In Person
 Business & Strategy |
|---|
Get referred to Pfizer
See people who can refer or advise you
- A good school-leaving qualification, such as Mittlere Reife, Fachhochschulreife, or Abitur, is required.
- Curiosity about business administration processes is required.
- Very good spoken and written German is required.
- Candidates should be open to new experiences and varied tasks.
- Candidates should be engaged and motivated to actively shape their training.
- Participate actively in various training departments and acquire relevant specialist knowledge through hands-on work.
- Take on responsibility quickly and independently complete smaller projects within a supportive team.
- Gain insight into modern office and communication systems and attend internal instruction.
- Learn the key commercial areas, including materials management, finance, and human resources, during the three-year industrial business management apprenticeship.
- Work as a full team member, contribute actively, and gain practical experience.
- Participate in real projects from the beginning of the apprenticeship.
- Team spirit and willingness to take responsibility from the outset and contribute ideas.
Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.
Company Size
10,001+
Company Stage
IPO
Headquarters
New York City, New York
Founded
1849
Get referred to Pfizer
See people who can refer or advise you
Simplify's Take
What believers are saying
- FDA approved Pfizer-BioNTech’s XFG COVID vaccine on August 27, 2026 for fall shipping.
- Pfizer raised 2026 revenue guidance to $60.5 billion-$62.5 billion on August 4, 2026.
- Padcev and Lorbrena grew in Q2 2026, proving post-Seagen oncology momentum.
What critics are saying
- Eliquis loses U.S. exclusivity in 2028, opening a rapid generic cliff.
- Arbutus filed international LNP patent suits on July 16, 2026 against Pfizer-BioNTech.
- Comirnaty and Paxlovid remain shrinking as FDA narrows eligibility and COVID demand fades.
What makes Pfizer unique
- Pfizer’s Seagen acquisition gives it a stronger oncology engine than pure-vaccine peers.
- Eliquis and Vyndaqel diversify revenue beyond COVID, with Q2 2026 growth.
- Pfizer’s global commercial scale still pushes products through pharmacies, hospitals, and governments.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Relocation Assistance
Growth & Insights and Company News
6 month growth
↓ -5%1 year growth
↓ -5%2 year growth
↓ -5%AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.
Pfizer received FDA approval for its updated Comirnaty COVID-19 vaccine on Thursday, with deliveries to pharmacies and clinics beginning immediately. The company's shares were trading at $27.9079 on 28 August. However, the market opportunity has significantly narrowed from pandemic levels. Eligibility is now limited to adults aged 65 and older, plus higher-risk patients aged 5 through 64. Despite Comirnaty having distributed over five billion doses worldwide historically, today's revenue potential is considerably more constrained. Pfizer faces competition from Moderna and the Novavax-Sanofi protein vaccine for this smaller patient pool. The company's current share price sits 5.27% above its estimated value of $26.51, suggesting investors are paying a premium before actual uptake and commercial results become clear.
Pfizer and BioNTech have received US Food and Drug Administration (FDA) approval for their 2026-2027 COVID-19 vaccine targeting the XFG variant. The vaccine is approved for adults aged 65 and older, and individuals aged 5 to 64 with underlying conditions that increase risk of severe COVID-19 outcomes. The FDA approval is based on clinical, non-clinical and real-world data demonstrating the vaccine generates strong immune responses against currently circulating SARS-CoV-2 variants, including XFG and other contemporary lineages. The XFG variant was selected following FDA guidance for fall 2026 vaccine composition. The vaccine will begin shipping immediately and will be available in US pharmacies, hospitals and clinics within days. To date, more than five billion doses of COMIRNATY have been distributed globally.
Pfizer and Johnson & Johnson are navigating patent cliffs as key drugs lose exclusivity, with their latest results showing differing stages of transition. Pfizer's revenue excluding COVID products grew 5% operationally in Q2 2026, with newer medicines like Padcev and Vyndaqel contributing. The company expects $9.7 billion in cost savings through 2029 to support margins during the transition. Johnson & Johnson's Innovative Medicine sales rose 7.8%, despite Stelara revenue declining 55%. Tremfya sales surged 72.5% to $2 billion, helping offset losses alongside growth from oncology and neuroscience products. Johnson & Johnson raised 2026 guidance, with reported sales expected to reach $101.1 billion and adjusted EPS of $11.68. Its MedTech division provides additional diversification that pure pharmaceutical company Pfizer lacks, suggesting Johnson & Johnson's transition is more advanced.
Intel CEO Lip-Bu Tan purchased nearly $10 million worth of shares as part of the chipmaker's recent stock offering, signalling confidence in the company's turnaround. Intel recently reported revenues of $16.1 billion, growing 25% year-over-year, with its Data Centre and AI business unit seeing revenue surge nearly 60% to $6.3 billion. CoStar Group founder and CEO Andrew Florance purchased 83,300 shares totalling roughly $2.5 million. Pfizer CEO Albert Bourla similarly invested, purchasing 38,000 shares for just over $1 million. These insider purchases reflect executives' confidence in their companies' longer-term outlook, with investors often viewing such moves as a positive signal.